| Symbol | VRDN |
|---|---|
| Name | VIRIDIAN THERAPEUTICS, INC.\DE |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceutical Preparations |
| Address | 221 CRESCENT STREET, WALTHAM, MA 02453 |
| Telephone | 617.272.4600 |
| Fax | — |
| — | |
| Website | https://www.viridiantherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001590750 |
| Description | Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease. Additional info from NASDAQ: |
Tripuraneni Radhika 🟡 adjusted position in 0 shares (1 derivative) of Viridian Therapeutics, Inc.\DE (VRDN) at $13.21 ($1.1M) Transaction Date: Aug 14, 2026 | Filing ID: 355735
Read moreNew Form SCHEDULE 13G/A - Viridian Therapeutics, Inc.\DE <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001104659-26-097208 <b>Size:</b> 12 KB
Read moreNew Form SCHEDULE 13G/A - Viridian Therapeutics, Inc.\DE <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001907884-26-000016 <b>Size:</b> 9 KB
Read moreNew Form SCHEDULE 13G/A - Viridian Therapeutics, Inc.\DE <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001172661-26-003486 <b>Size:</b> 11 KB
Read moreNew Form SCHEDULE 13G - Viridian Therapeutics, Inc.\DE <b>Filed:</b> 2026-08-07 <b>AccNo:</b> 0000093751-26-000558 <b>Size:</b> 8 KB
Read moreViridian Therapeutics, Inc. - Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results
Read moreViridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results
Read moreAjer Jeffrey Robert 🟢 acquired 32.3K shares (1 derivative) of Viridian Therapeutics, Inc.\DE (VRDN) at $18.48 Transaction Date: Jul 01, 2026 | Filing ID: 294560
Read moreMoses Jennifer K. 🟢 acquired 32.3K shares (1 derivative) of Viridian Therapeutics, Inc.\DE (VRDN) at $18.48 Transaction Date: Jul 01, 2026 | Filing ID: 294556
Read moreGheuens Sarah 🟢 acquired 32.3K shares (1 derivative) of Viridian Therapeutics, Inc.\DE (VRDN) at $18.48 Transaction Date: Jul 01, 2026 | Filing ID: 294552
Read more